Table 2 Characteristics of basket trials for disease-modifying agents in neurodegenerative disorders
From: The role of basket trials in drug development for neurodegenerative disorders
Drug | Number of trials | CADRO target | NDDs included |
|---|---|---|---|
ATH-1017 | 1 | Neuroprotection | PD, DLB |
BIIB092 | 1 | Tau extracellular transmission | FTLD, CBD, CTE |
Davunetide (AL-108, NAP) | 1 | Tau aggregation | PSP, CBD, FTLD |
Deferiprone | 1 | Oxidative stress | ALS, PD |
Insulin | 1 | Insulin resistance | PD, MSA |
Latrepirdine (dimebon) | 5 | Bioenergetic mitochondrial agent | HD, AD |
LMTM (TRx0237, LMT-X) | 1 | Tau aggregation | FTLD, AD |
Metformin | 1 | Insulin resistance | FTLD, ALS |
NBMI (N,N′-bis(2-mercaptoethyl) isophthalamide) | 1 | Mercury chelation (oxidative stress) | PSP, MSA |
Posiphen | 1 | Protein aggregation | PD, AD |
TPI-287 (abeotaxane) | 1 | Tau microtubule stabilizer | CBD, PSP |
Traneurocin (N-831) | 1 | Neurogenesis | DLB, AD |
Warfarin | 1 | Vascular (anticoagulant) | AD, HD |
Zoledronic acid | 1 | Bone loss prevention | PD, DLB, PSP, MSA |